SH 05 - Genitourinary Cancer - Science Highlights

session DESCRIPTION

The following abstracts will be highlighted in this session:

• LBA 04 — A Double-Blinded Placebo-Controlled Biomarker Stratified Randomized Trial of Apalutamide (APA) and Radiotherapy for Recurrent Prostate Cancer (NRG GU006, BALANCE trial) — Daniel Spratt
• 114 — Phase 3, Randomized, Placebo Controlled Clinical Trial of CAN-2409+Prodrug in Combination with Standard of Care External Beam Radiation (EBRT) for Newly Diagnosed Localized Prostate Cancer — Glen Gejerman
• 148 — Stereotactic Intensity Modulated Radiotherapy after Radical Prostatectomy (SCIMITAR): Four-Year Outcomes of a Phase II Clinical Trial — Jesus Juarez Casillas
• 2 — Bladder Adjuvant Radiotherapy (BART): Clinical Outcomes from a Phase III Multicenter Randomized Controlled Trial — Vedang Murthy
• 1 — Primary Results from NRG-GU005: A Phase III Trial of SBRT vs. Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer — Rodney Ellis
• 3 — 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer; Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial — Amar Kishan